Crossmark

Short- and long-term outcomes after colonic self-expandable metal stent placement for malignant large-bowel obstruction as a bridge to surgery focus on the feasibility of the laparoscopic approach: a retrospective, single center study

Crossref DOI link: https://doi.org/10.1186/s12957-020-02039-8

Published Online: 2020-10-13

Published Print: 2020-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Tajima, Jesse Yu

Matsuhashi, Nobuhisa

Takahashi, Takao

Mizutani, Chika

Iwata, Yoshinori

Kiyama, Shigeru

Kubota, Masaya

Ibuka, Takashi

Araki, Hiroshi

Shimizu, Masahito

Doi, Kiyoshi

Yoshida, Kazuhiro
License Information

Text and Data Mining valid from 2020-10-13

Version of Record valid from 2020-10-13
More Information

Article History

Received: 28 June 2020

Accepted: 29 September 2020

First Online: 13 October 2020

Ethics approval and consent to participate

: This study was approved by the Central Ethics Committee of Gifu University (approved number: 2019-195).

: Not applicable

: TT: Takeda Pharmaceutical Co., Ltd., Sanofi (H), Yakult Honsha; KY: reports grants and personal fees from Taiho Pharm, Asahi Kasei Pharma, Chugai Pharm., Covidien Japan, Daiichi Sankyo, Eisai, Eli Lilly Japan, Johnson & Johnson, MerkSerono, MSD, Nippon Kayaku, Novartis, Ono Pharm., Otsuka Pharm., Sanofi, Takeda Pharm., Tsumura, Yakult Honsha; grants from Abbott, Abbvie, Astellas, Biogen Japan, Celgene, GlaxoSmithKline, KCI, Koninklijke Philips, Kyowa Kirin, Meiji Seika Pharma, Toray Medical; personal fees from AstraZeneka, Bristol-Myers Squibb, Denka, EA Pharma, Olympus, Pfizer, Sanwa Kagaku Kenkyusho, SBI Pharma, Teijin Phamra, TERUMO, outside the submitted work.

Document is current

Any future updates will be listed below